menu
    • menu
    [{"orgOrder":0,"company":"LipoMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Promitil","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LipoMedix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Undisclosed"},{"orgOrder":0,"company":"LipoMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Promitil","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LipoMedix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Undisclosed"},{"orgOrder":0,"company":"LipoMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Promitil","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LipoMedix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Undisclosed"},{"orgOrder":0,"company":"LipoMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Promitil","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LipoMedix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Undisclosed"},{"orgOrder":0,"company":"LipoMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Promitil","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LipoMedix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LipoMedix \/ Undisclosed"},{"orgOrder":0,"company":"LipoMedix","sponsor":"ForDoz","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LipoMedix \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"LipoMedix \/ LipoMedix"},{"orgOrder":0,"company":"LipoMedix","sponsor":"ForDoz","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LipoMedix \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"LipoMedix \/ LipoMedix"}]

    Find Clinical Drug Pipeline Developments & Deals by LipoMedix

    Menu

    LipoMedix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Promitil

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed Aft...

                            Details : Promitil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 27, 2024

                            Lead Product(s) : Promitil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegylated liposomal Mitomycin-c ProDrug,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : ForDoz

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix

                            Details : Fordoz will support LipoMedix to develop and manufacture Promitil in the United States. Promitil's unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemor...

                            Product Name : Promitil

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 10, 2021

                            Lead Product(s) : Pegylated liposomal Mitomycin-c ProDrug,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : ForDoz

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegylated liposomal Mitomycin-c ProDrug,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : ForDoz

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil®

                            Details : LipoMedix's lead compound, Promitil® (PL-MLP), will be manufactured in the United States by ForDoz Pharma (ForDoz), specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex inje...

                            Product Name : Promitil

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 10, 2021

                            Lead Product(s) : Pegylated liposomal Mitomycin-c ProDrug,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : ForDoz

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Promitil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malig...

                            Details : Promitil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 28, 2021

                            Lead Product(s) : Promitil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Promitil,Bevacizumab,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investiga...

                            Details : Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2020

                            Lead Product(s) : Promitil,Bevacizumab,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Promitil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patient...

                            Details : Promitil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2019

                            Lead Product(s) : Promitil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed

                            LipoMedix

                            Israel arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Promitil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients W...

                            Details : Promitil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 12, 2012

                            Lead Product(s) : Promitil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth